Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.

<h4>Background</h4>HVTN 100 evaluated the safety and immunogenicity of an HIV subtype C pox-protein vaccine regimen, investigating a 12-month booster to extend vaccine-induced immune responses.<h4>Methods and findings</h4>A phase 1-2 randomized double-blind placebo-controlled trial enrolled 252 part...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Fatima Laher, Zoe Moodie, Kristen W Cohen, Nicole Grunenberg, Linda-Gail Bekker, Mary Allen, Nicole Frahm, Nicole L Yates, Lynn Morris, Mookho Malahleha, Kathryn Mngadi, Brodie Daniels, Craig Innes, Kevin Saunders, Shannon Grant, Chenchen Yu, Peter B Gilbert, Sanjay Phogat, Carlos A DiazGranados, Marguerite Koutsoukos, Olivier Van Der Meeren, Carter Bentley, Nonhlanhla N Mkhize, Michael N Pensiero, Vijay L Mehra, James G Kublin, Lawrence Corey, David C Montefiori, Glenda E Gray, M Juliana McElrath, Georgia D Tomaras
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Public Library of Science (PLoS) 2020-02-01
Serie:	PLoS Medicine
Accesso online:	https://doi.org/10.1371/journal.pmed.1003038
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!